FXYD5

Across TCGA pan-cancer cohorts, FXYD5 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FXYD5 data layer compared with 28 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher FXYD5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FXYD5 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, BLCA, and HNSC are the cancer types where FXYD5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.111	0.750	<.001	18	view →
BLCA	OS	Median	IV	0.051	0.600	<.001	12	view →
HNSC	DFS	Median	All	0.185	0.603	.032	6	view →
UCEC	DFS	Median	II,III,IV	1.000	0.444	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FXYD5–LUAD (OS)

Open the LUAD breakdown →